Aspen
SENIOR MEMBER
- Joined
- Sep 18, 2019
- Messages
- 3,585
- Reaction score
- 1
- Country
- Location
Sorrento Therapeutics founder and CEO Dr. Henry Ji is defending his company after several days of volatility in its stock price following details on a potential COVID-19 antibody treatment.
The stock promptly exploded more than 200% over the next day or so of trading as investor optimism grew on the potential of Sorrento’s drug. It’s not uncommon to see small-cap biotech stocks act like this on the slightest bit of promising news regarding a new drug. Seeing as COVID-19 is such a large global issue, any indications of a treatment would likely be handsomely rewarded by the market.
Sorrento shares have fallen about 50% from their highs on the news, perhaps raising questions in the market on what Sorrento actually has discovered drug wise. Also worth noting that like other emerging biotech companies, Sorrento isn’t profitable — which adds to the risk profile of the stock.
Ji is unfazed by the stock price volatility. He says his team is focused on getting a COVID-19 treatment to market.
“So what we are focusing on instead of watching the stock going up or going down, we are focusing on making sure we have the real deal. So you have the antibody that can prevent the virus from infecting healthy cells. That means you will have a real product. If you have a real product, eventually the stock will be reflecting the assets you have. And we believe right now probably there is a lot of investors excited about the story,” Ji said.
Ji added, “In the short-term, the stock price is a voting machine and eventually a weighing machine, you know, as Warren Buffett said. So I think eventually it will reflect the value we have here.
https://finance.yahoo.com/news/sorr...are-not-a-pump-and-dump-scheme-155253179.html
The stock promptly exploded more than 200% over the next day or so of trading as investor optimism grew on the potential of Sorrento’s drug. It’s not uncommon to see small-cap biotech stocks act like this on the slightest bit of promising news regarding a new drug. Seeing as COVID-19 is such a large global issue, any indications of a treatment would likely be handsomely rewarded by the market.
Sorrento shares have fallen about 50% from their highs on the news, perhaps raising questions in the market on what Sorrento actually has discovered drug wise. Also worth noting that like other emerging biotech companies, Sorrento isn’t profitable — which adds to the risk profile of the stock.
Ji is unfazed by the stock price volatility. He says his team is focused on getting a COVID-19 treatment to market.
“So what we are focusing on instead of watching the stock going up or going down, we are focusing on making sure we have the real deal. So you have the antibody that can prevent the virus from infecting healthy cells. That means you will have a real product. If you have a real product, eventually the stock will be reflecting the assets you have. And we believe right now probably there is a lot of investors excited about the story,” Ji said.
Ji added, “In the short-term, the stock price is a voting machine and eventually a weighing machine, you know, as Warren Buffett said. So I think eventually it will reflect the value we have here.
https://finance.yahoo.com/news/sorr...are-not-a-pump-and-dump-scheme-155253179.html
